title: Radiation maculopathy treated with intravitreal bevacizumab.
abstract: METHODS
  A 47 year-old woman with a choroidal melanoma developed a macular oedema secondary to radiation therapy 75 months after brachytherapy plaque. The patient received 3 intravitreal Bevacizumab injections.
  
  
  CONCLUSIONS
  The patient had a good response to bevacizumab treatment. In fact, there was a reduction in the macular oedema measured by optical coherence tomography (OCT) scan, as well as an improvement in best corrected visual acuity. There was no recurrence of macular oedema, and visual acuity remained stable after 3-years follow-up.
authors.affiliation: Unidad de Gestión Clínica de Oftalmología, Hospital Universitario Virgen del Rocío, Sevilla, España.
authors.forename: J L
authors.initials: JL
authors.lastname: Sánchez-Vicente
authors.affiliation: Unidad de Gestión Clínica de Oftalmología, Hospital Universitario Virgen del Rocío, Sevilla, España.
authors.forename: A
authors.initials: A
authors.lastname: Muñoz-Morales
authors.affiliation: Unidad de Gestión Clínica de Oftalmología, Hospital Universitario Virgen del Rocío, Sevilla, España. Electronic address: mpazgalvan@gmail.com.
authors.forename: M P
authors.initials: MP
authors.lastname: Galván-Carrasco
authors.affiliation: Unidad de Gestión Clínica de Oftalmología, Hospital Universitario Virgen del Rocío, Sevilla, España.
authors.forename: A
authors.initials: A
authors.lastname: Castilla-Lázpita
authors.affiliation: Unidad de Gestión Clínica de Oftalmología, Hospital Universitario Virgen del Rocío, Sevilla, España.
authors.forename: C
authors.initials: C
authors.lastname: Vital-Berral
authors.affiliation: Unidad de Gestión Clínica de Oftalmología, Hospital Universitario Virgen del Rocío, Sevilla, España.
authors.forename: A
authors.initials: A
authors.lastname: Alfaro-Juárez
authors.affiliation: Unidad de Gestión Clínica de Oftalmología, Hospital Universitario Virgen del Rocío, Sevilla, España.
authors.forename: T
authors.initials: T
authors.lastname: Rueda-Rueda
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000008:administration & dosage / Q000627:therapeutic use*; D001918:Brachytherapy / Q000009:adverse effects*; D002832:Choroid Hemorrhage / Q000209:etiology; D002830:Choroid Neoplasms / Q000532:radiotherapy*; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D019654:Lens Implantation, Intraocular; D008269:Macular Edema / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000209:etiology; D008545:Melanoma / Q000532:radiotherapy*; D008875:Middle Aged; D018918:Phacoemulsification; D011183:Postoperative Complications / Q000188:drug therapy / Q000209:etiology; D011832:Radiation Injuries / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000209:etiology; D041623:Tomography, Optical Coherence
chemical_list: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab
keywords: Bevacizumab; Choroidal melanoma; Edema macular; Macular oedema; Maculopatía por radiación; Melanoma coroideo; Radiation maculopathy; Radiation retinopathy; Retinopatía por radiación